CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park
California
94025
United States
118 articles with CohBar, Inc.
-
CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
8/15/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress.
-
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022Company to host conference call and webcast at 5:00 p.m. ET
8/1/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 second quarter financial results after the market closes on Monday, August 15, 2022.
-
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
7/12/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company’s Board, effective July 11, 2022.
-
CohBar to Participate at Upcoming Conferences in June 2022
6/7/2022
CohBar, Inc. announced that its Chief Executive Officer, Dr. Joseph Sarret, will participate at two upcoming conferences.
-
CohBar to Present at the H.C. Wainwright Global Investment Conference
5/19/2022
CohBar, Inc. announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.
-
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
5/16/2022
CohBar, Inc. reported its financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.
-
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal
5/12/2022
CohBar, Inc. announced that The Nasdaq Capital Market has granted the Company’s request for a 180 day extension, or until November 7, 2022, of the period to regain compliance with its minimum bid price per share requirement.
-
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
5/2/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 first quarter financial results after the market closes on Monday, May 16, 2022.
-
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
3/29/2022
CohBar, Inc., a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022Company to host conference call and webcast at 5:00 p.m. ET
3/15/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2021 fourth quarter and full year financial results after the market closes on Tuesday, March 29, 2022.
-
You are what you eat, and your defense system notices that.
-
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
1/3/2022
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference.
-
CohBar Announces Changes to its Board of Directors and R&D Leadership
12/17/2021
Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research.
-
CohBar’s CEO to Participate in Upcoming BIO Webinar
11/29/2021
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced its Chief Executive Officer, Joseph Sarret, MD, JD, will be a participant on the BIO webinar titled “Leveraging JPM Week to Achieve Business Development Goals” on December 2, 2021 at 1:00pm ET.
-
CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update
11/15/2021
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported its financial results for the third quarter ended September 30, 2021.
-
CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021Company to host conference call at 5:00 p.m. ET
11/1/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 2021 financial results after the market closes on Monday, November 15, 2021.
-
CohBar Announces Proposed Public Offering of Common Stock and Warrants - Oct 27, 2021
10/27/2021
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced a proposed underwritten public offering of shares of the Company’s common stock and accompanying warrants to purchase common stock.
-
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
10/13/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that data from its CB4211 Phase 1a/1b clinical study have been selected for presentation during the late-breaking poster session at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting® 2021).
-
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
10/5/2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 5th Annual NASH Investor Conference, being held virtually on October 12, 2021.
-
CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors
9/15/2021
CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced the appointment of Joanne Yun, Ph.D. as an independent director on the company’s Board, effective September 14, 2021.